Phase 1 Trial of Autologous Bone Marrow Stem Cell Transplantation in Patients with Spinal Cord Injury

Table 1

The total amount of autologous bone marrow and the detailed number of final bone marrow stem cell products.

Patients	Bone marrow (mL)	Total cells (×10^6)	⁢CD45		⁢Mononuclear cells		⁢Mesenchymal cells; ⁢STRO-1+/CD271+		⁢CD34
			%	Number of cells (×10^6)	%	Number of cells (×10^6)	%	Number of cells (×10^3)	%	Number of cells (×10^6)
1	120	536	50	268	28	150	0.04	214	1.5	7.0
2	100	516	53	284	34	176	0.02	103	1.4	7.2
3	100	531	51	271	31	165	0.03	159	1.4	7.4
4	120	542	54	293	38	206	0.04	217	1.5	8.1
5	100	405	55	223	45	181	0.05	713	0.9	3.6
6	100	964	55	530	40	386	0.04	384	1.5	14.5
7	120	620	50	310	37	229	0.03	186	0.8	5.0
8	100	903	58	524	41	375	0.02	181	0.9	8.1
9	100	749	61	457	35	262	0.01	75	1.5	12.0
10	120	902	55	491	29	261	0.02	181	2.5	22.6
11	100	748	61	456	34	261	0.01	74	1.5	11.2
12	100	526	51	267	27	151	0.04	214	1.5	7.9
13	120	512	52	283	33	175	0.02	103	1.4	7.2
14	110	559	81	451	33	187	0.04	210	7.5	41.9
15	100	690	48	330	36	245	0.04	284	2.4	16.6
16	120	542	52	280	27	145	0.05	260	0.9	4.9
17	120	628	49	310	34	214	0.03	210	2.7	17.0
18	100	696	42	294	44	308	0.02	148	2.6	18.1